Literature DB >> 8970015

Do we need full compliance data for population pharmacokinetic analysis?

P Girard1, L B Sheiner, H Kastrissios, T F Blaschke.   

Abstract

For population pharmacokinetic analysis of multiple oral doses one of the key issues is knowing as precisely as possible the dose inputs in order to fit a model to the input-output (dose-concentration) relationship. Recently developed electronic monitoring devices, placed on pill containers, permit precise records to be obtained over months, of the time/date opening of the container. Such records are reported to be the most reliable measurement of drug taking behavior for ambulatory patients. To investigate strategies for using and summarizing this new abundant information, a Markov chain process model was developed, that simulates compliance data from real data from electronically monitored patients, and data simulations and analyses were conducted. Results indicate that traditional population pharmacokinetic analysis methods that ignore actual dosing information tend to estimate biased clearance and volume and markedly overestimate random interindividual variability. The best dosing information summarization strategies consist of initially estimating population pharmacokinetic parameters, using no covariates and only a limited number of dose records, the latter chosen based on an a priori estimate of the half-life of the drug in the compartment of interest; then resummarizing the dose records using either population or individual posterior Bayes parameter estimates from the first population fit; and finally reestimating the population parameters using the newly summarized dose records. Such summarization strategies yield the same parameter estimates as using full dosing information records while reducing by at least 75% the CPU time needed for a population pharmacokinetic analysis.

Entities:  

Mesh:

Year:  1996        PMID: 8970015     DOI: 10.1007/bf02353671

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  16 in total

1.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

3.  An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly.

Authors:  E J Antal; T H Grasela; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

4.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  How often is medication taken as prescribed? A novel assessment technique.

Authors:  J A Cramer; R H Mattson; M L Prevey; R D Scheyer; V L Ouellette
Journal:  JAMA       Date:  1989-06-09       Impact factor: 56.272

6.  Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.

Authors:  Y Merlé; F Mentré; A Mallet; A H Aurengo
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

7.  Estimating bioavailability when clearance varies with time.

Authors:  M O Karlsson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-06       Impact factor: 6.875

8.  Prediction of diltiazem plasma concentration curves from limited measurements using compliance data.

Authors:  A Rubio; C Cox; M Weintraub
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 9.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

10.  Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.

Authors:  D M Waterhouse; K A Calzone; C Mele; D E Brenner
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  30 in total

1.  The formulation of the principle of superposition in the presence of non-compliance and its applications in multiple dose pharmacokinetics.

Authors:  W Wang; S P Ouyang
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Design and power of a population pharmacokinetic study.

Authors:  P I Lee
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

4.  Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders.

Authors:  Takeshi Shiiki; Yukiya Hashimoto; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 5.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 6.  On some "disadvantages" of the population approach.

Authors:  Jerry R Nedelman
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 7.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

8.  Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.

Authors:  Ayyappa Chaturvedula; Michael J Fossler; Craig W Hendrix
Journal:  J Clin Pharmacol       Date:  2013-11-30       Impact factor: 3.126

9.  Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.

Authors:  Emilie Hénin; Michel Tod; Véronique Trillet-Lenoir; Catherine Rioufol; Brigitte Tranchand; Pascal Girard
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Lazy sunday afternoons: the negative impact of interruptions in patients' daily routine on adherence to oral antidiabetic medication. A multilevel analysis of electronic monitoring data.

Authors:  M Vervloet; P Spreeuwenberg; M L Bouvy; E R Heerdink; D H de Bakker; L van Dijk
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.